Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!
efficacious compared with VEN+O with an incremental- cost - effectiveness -ratio of $2,139,180/quality-adjusted life-year versus VEN+O and not a cost - effective option in Canada. Probabilistic analyses show ...
savings compared with treat-to-progression chemotherapy-free regimens.OBJECTIVE:To evaluate the cost - effectiveness of 12 months fixed-duration VenG in first-line treatment of unfit patients with CLL from ...
, ofatumumab, or obinutuzumab ) or ibrutinib as single agent. Despite the evolving treatment paradigm toward targeted therapy, it is likely that rituximab (plus chemotherapy), with or without targeted agents ...
in the two groups (89% vs. 87%), with PFS curves separating during maintenance therapy. Notably, obinutuzumab was associated with higher rates of infusion reactions (59% vs. 49%). Additionally, the side‐ effect ...
in the frontline setting for all patients. The treatment strategy that is effective in this population of patients should then be compared with current frontline treatment approaches for newly diagnosed follicular ...
spending actually decreased 0.8% compared with the previous year.2 However, this trend is anticipated to begin to reverse by 2014. Many factors influence future drug spending. Increased spending can ...
to induce cytotoxic effects . mAbs can elicit anti-cancer outcomes by either direct or immune-mediated mechanisms. Direct effects include growth arrest (e.g., blocking of growth receptor dimerization or ligand ...
carefully examine their own local drug utilization patterns to determine their own organization’s anticipated spending in 2015. Healthcare reforms aimed at reducing costs , or “bending the cost curve,” while ...
, doxorubicin, vincristine, and prednisone with rituximab [95]; and bendamustine and rituximab (BR) [96–98]. Their comparative effectiveness versus R‐CHOP is unknown, but retrospective data in unfit and frail ...
, early stage R-CHOP ± RT SLL/CLL Ibrutinib /FCR/bendamustine ± rituximab/ obinutuzumab + chlorambucil Follicular or marginal zone lymphoma, advanced stage Observation/BR/R-CVP/R-CHOP/rituximab/single agent ...
Access the full text.
Sign up today, get unlimited access with DeepDyve Pro!